Cart is empty Targeting part of an antiviral pathway triggered by the accumulation of a key pathogen shared in Alzheimer’s disease and frontotemporal dementia may one day offer a new therapeutic approach to deterring or delaying cognitive decline, according to preclinical research led by Weill Cornell Medicine scientists.
Leave A Comment